Government response to the Health Select Committee report on the future of NICE

In its response to the Health Select Committee’s report on the future role of the National Institute for Health and Clinical Excellence (NICE), the government has confirmed NICE will:

  • have a crucial role in the future value-based pricing arrangements for branded medicines.
  • build on its current drug evaluation processes by giving it broader scope to assess a medicine’s benefits and costs. The aim is to make sure that the price the NHS pays for new medicines is more closely linked to their value to NHS patients and society.

Read more


In News, NICE guidance | Tagged ,

Leave a Reply

Leave a comment